Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 3:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 1,866 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: First Treatment Period Clear all

Conditions: Solid Tumours, Sarcoma, HNSCC, Non Small Cell Lung Cancer, NSCLC, Colorectal Cancer (CRC), Myxofibrosarcoma (MFS), Solitary Fibrous Tumors, Dedifferentiated Liposarcoma, Undifferentiated Pleomorphic Sarcoma (UPS), Leiomyosarcoma, Leiomyosarcoma (LMS), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic, Gastric / Gastroesophageal Junction Adenocarcinoma
Interventions: OKN4395, Pembrolizumab, Fasting, Fed, H2 Receptor Antagonist; Drug · Combination Product · Other
Lead sponsor: Epkin; Industry
Eligibility: 18 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Beverly Hills, California • Santa Monica, California • Houston, Texas

Conditions: Parkinson Disease (PD)
Interventions: Overactive bladder antimuscarinic deprescribing; Drug
Lead sponsor: Corporal Michael J. Crescenz VA Medical Center; Federal
Eligibility: 60 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Cancer, Solid Tumor
Interventions: IMC-1121B, Moxifloxacin, Diphenhydramine; Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 7
States / cities: Atlanta, Georgia • Metairie, Louisiana • Ann Arbor, Michigan + 4 more

Conditions: Cancer
Interventions: EXCAP, MAAT, ECO; Behavioral
Lead sponsor: University of Rochester; Other
Eligibility: 65 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Obesity, Overweight
Interventions: NNC0174-0833, Semaglutide, Placebo (NNC0174-0833); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Pneumothorax
Interventions: Primary Surgery Group, Initial Non-operative management; Procedure
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 5 Years to 18 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Generalized Myasthenia Gravis
Interventions: ALXN1720, Placebo; Combination Product
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 23
States / cities: Orange, California • Fort Collins, Colorado • Washington D.C., District of Columbia + 20 more

Conditions: Acute Coronary Syndrome, Physical Inactivity
Interventions: Positive Psychology + Motivational Interviewing; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 95 Years
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 1 Diabetes
Interventions: ePID closed loop system, liraglutide; Device · Drug
Lead sponsor: Jennifer Sherr; Other
Eligibility: 18 Years to 40 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Electronic Nicotine Delivery Systems, Tobacco Products, Cigarette Smoking
Interventions: EQUIP, Standard Care; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 26 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Gout Chronic
Interventions: Pegloticase 8 MG/ML [Krystexxa], MMF, Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Healthy
Interventions: ACT-1004-1239, Placebo, ACT-1004-1239 (Food-effect subpart), Placebo (Food-effect subpart); Drug · Other
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pain, Back, Pain, Acute, Sleep Disorder, Sleep Disorders, Circadian Rhythm, Sleep, Sleep Deprivation, Insomnia
Interventions: Drug- free, non-invasive patch (FREEDOM or REM Patch) with haptic vibrotactile trigger technology (VTT) Other Names:, Sham Patch without haptic vibrotactile trigger technology (VTT); Device
Lead sponsor: SuperPatch Limited LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Tyrone, Georgia

Conditions: Cancer, Depression
Interventions: Behavioral Activation Therapy App, Telehealth Delivered Behavioral Activation; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Chronic Obstructive Pulmonary Disease, Lung Cancer
Interventions: Pulmonary Rehab; Other
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Chronic Pain
Interventions: Behavior Change Coaching, Nutrition, Autonomic Recalibration, Dry Needling, Osteopathic Manipulative Treatment, Counseling Psychology, Multiple Treatments; Behavioral · Other · Procedure
Lead sponsor: Edward Via Virginia College of Osteopathic Medicine; Other
Eligibility: 21 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Auburn, Alabama

Conditions: Hot Flashes, Menopause, Vasomotor Disturbance, Sleep
Interventions: Cognitive Behavioral Therapy-Insomnia (CBT-I), Menopause Education Control (MEC); Behavioral
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Systemic Lupus Erythematosus
Interventions: Cenerimod 0.5 mg, Cenerimod 1 mg, Cenerimod 2 mg, Cenerimod 4 mg, Placebo, cenerimod 2 mg (ex-4 mg); Drug
Lead sponsor: Viatris Innovation GmbH; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 427 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 29
States / cities: Anniston, Alabama • La Jolla, California • Los Alamitos, California + 25 more

Conditions: Major Depressive Disorder
Interventions: SSRI, CBT; Drug · Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 55 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Addiction, Addiction Disorders
Interventions: SKY Breathing Program; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Sanborn, New York

Conditions: Advanced Solid Tumors
Interventions: ALKS 4230, ALKS 4230 + pembrolizumab; Drug
Lead sponsor: Mural Oncology, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 12
States / cities: Denver, Colorado • Port Saint Lucie, Florida • Tampa, Florida + 9 more

Conditions: Extensive Stage-small Cell Lung Cancer
Interventions: Ifinatamab deruxtecan, Atezolizumab, Carboplatin; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 26
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more

Conditions: Systematic Acupuncture
Interventions: Acupuncture Treatments; Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 20 Years to 60 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: Tapentadol ER Tamper-resistant Formulation (TRF), Tapentadol ER Prolonged-Release 2 (PR2); Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Lincoln, Nebraska

Search by objective public record fields.

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

Pilot Deprescribing of Antimuscarinic Overactive Bladder Medications in Parkinson Disease

Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes

Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors

A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese

Primary Versus Delayed Surgical Therapy for Pediatric Spontaneous Pneumothorax

Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

Positive Emotions Following Acute Cardiac Events

Effect of Liraglutide on Automated Closed-loop Glucose Control in Type 1 Diabetes

Development of a Mobile Health Intervention for Electronic Cigarette Use Among Young Adults

REduCing Immunogenicity to PegloticasE (RECIPE) Study

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of ACT-1004-1239 in Healthy Male Subjects

Relieving Pain and Improving Sleep: Evaluating Topical Pain Relief and Sleep Patches

Optimizing Care for Cancer Survivors With Depression: Project 3

Accelerated Pulmonary Rehabilitation in the Preoperative Period

VCOM Pain Free Research Collaborative

MsFLASH-04: Pilot Trial: Telephone Behavioral Therapy for Menopause-related Sleep Disturbance

Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus

Imaging Antidepressant vs. Cognitive Behavior Therapy Effects on Unipolar Depression

Effects of Breathwork and Meditation on Addiction Recovery

A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

Acupuncture for Stroke Recovery

A Pivotal Study to Evaluate the Bio-equivalence of the Tapentadol Extended-Release (ER) Tamper-resistant Formulation (TRF) Tablet to the Current Tapentadol ER Prolonged-release 2 (PR2) Tablet